GenFleet Therapeutics (Shanghai) Inc. is a clinical-stage biotechnology company specializing in the development of innovative therapies for oncology and immunology. Founded in 2017 and headquartered in Shanghai, GenFleet targets significant unmet medical needs by focusing on first-in-class drug candidates, particularly for various solid tumors and autoimmune diseases. The company distinguishes itself through a proprietary, fully integrated research and development platform, supporting a robust pipeline of both small molecule and biologic therapies with novel mechanisms. One of GenFleet’s leading achievements is Dupert® (fulzerasib), the first approved KRAS G12C inhibitor in China and the third globally, which demonstrates the company’s advanced capabilities in targeted cancer treatments. GenFleet’s portfolio also includes other notable products such as GFH375, which is under global clinical evaluation for non-small cell lung cancer. The company maintains a strategy centered on global research collaborations and commercial partnerships, amplifying its market impact and contributing to the evolution of precision medicine within the pharmaceutical sector. Through its pioneering R&D efforts, GenFleet Therapeutics is positioned as a significant innovator in the biopharmaceutical industry.